Biosimilars of Rituximab-based Therapy for Treatment of B-cell Lymphoma: A Retrospective Analysis
Rituximab Biosimilar in B-cell Lymphoma Treatment
Keywords:
B-cell lymphoma, Biosimilar rituximab, EfficacyAbstract
Rituximab is a monoclonal anti-CD20 antibody used with chemotherapy to treat B-cell lymphoma. Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is a standard chemoimmunotherapy regimen for treating diffuse large B-cell lymphoma worldwide. As original rituximab is still expensive, so biosimilar of rituximab has been developed and used widely in many countries. Our objectives were to study the efficacy and safety of biosimilar rituximab for treatment of B-cell lymphoma in Thailand. Retrospective descriptive study was conducted in 84 patients with B-cell lymphoma. the patients received biosimilar rituximab plus CHOP chemotherapy in Ramathibodi and Pranangklao hospitals from January 2018 to December 2020. A total of 84 patients with B-cell lymphoma were evaluated and their mean age was 65 years (range, 25–88 years). Of all the patients, 59.5% had double expressor lymphoma expression, 63% had bulky disease, and 69% had high serum lactate dehydrogenase (LDH); and after 5 years of follow-up, 84.5% were found to have complete remission, 3.6% had partial remission and 11.9% had progressive disease. The median survival time was 50 months and the median progression-free survival was 53 months. Based on each IPI score 0–4, the overall survival periods were 45, 56, 48, 47 and 29 months, respectively (p-value < 0.001). Regarding adverse events, 9.5% had only mild infusion-related reactions and 90.5% had no adverse drug reactions. Thus, biosimilar rituximab and standard chemotherapy together are quite efficacious for treating B-cell lymphoma, causing just minor side effects.
References
Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012; 2(6): 676-90.
Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47(2): 115-23.
Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas. Future Oncol 2015; 11(9): 1327-42.
Salles G, Barrett M, Foà R, Maurer J, O’Brien S,Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 2017; 34(10): 2232-73.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12(11): 1013-22.
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as fi rst-line treatment for advanced follicular lymphoma. Blood 2005; 105(4): 1417-23.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-42.
Intragumtornchai T, Bunworasate U, Siritanaratkul N, Khuhapinant A, Nawarawong W, Norasetthada L, et al. Inferior progressionfree survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability. Leuk Lymphoma 2013; 54: 83-9.
Jurczak W, Długosz-Danecka M. Rituximab biosimilars in clinical practice. Leuk Lymphoma 2020; 61(7): 1523-24.
Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, et al. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 2016; 78(2): 353-9.
Roy PS, John S, Karankal S, Kannan S, Pawaskar P, Gawande J, et al. Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol 2013; 34(4): 292-8.
Kim WS, Coiffier B, Buske C, Ogura M, Kwak L, Jurczak W, et al. CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial. Ann Oncol 2017; 28: 94.
Rioufol C, Salles G. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Rev Anticancer Ther 2015; 15(5): 569-78.
สมาคมรูมาติสซั่มแห่งประเทศไทย. คำแถลงฉันทามติการใช้ยาชีววัตถุคล้ายคลึงในการรักษาโรครูมาติกและ ออโตอิมมูน ฉบับที่ 4. กรุงเทพฯ: สมาคมรูมาติสซั่ม แห่งประเทศไทย; 2566. หน้า 6-7.
Brink M, Kahle XU, Vermaat JSP, Zijlstra JM, Chamuleau M, Kersten MJ, et al. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv 2021;5(15): 2958-64.
กลุ่มนโยบายแห่งชาติด้านยา. ประกาศคณะกรรมการพัฒนาระบบยาแห่งชาติ เรื่องกำหนดราคากลางยา พ.ศ. 2562. [ออนไลน์]. 2562; [สืบค้น 1 กรกฎาคม 2566]; [1 หน้า]. เข้าถึงได้จาก: URL:https://ndi.fda.moph.go.th/drug_value/index.
Ding J, Leng Z, Gu H, Jing X. A novel prednisone premedication protocol significantly decreases infusion-related reactions of rituximab in newly diagnosed diffuse large B-cell lymphoma. Oncol Lett 2023; 25: 258. (7 pages).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 BULLETIN OF THE DEPARTMENT OF MEDICAL SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
